See the DrugPatentWatch profile for Blenrep
What is Blenrep (belantamab mafodotin)?
Blenrep is a cancer medicine called belantamab mafodotin. It is used to treat certain patients with multiple myeloma, where the disease has relapsed after other therapies [1].
Who is it for in multiple myeloma?
Blenrep is used for people with relapsed or refractory multiple myeloma after prior treatment, including regimens that have already been tried in the past for the patient’s disease course [1].
How is Blenrep given?
Blenrep is given by intravenous infusion (through the bloodstream). Treatment is typically delivered in cycles, with dosing managed by the oncology care team [1].
What side effects do patients ask about most?
A key concern with Blenrep is eye toxicity (including blurred vision and other corneal-related effects), which requires monitoring during treatment [1]. Patients are usually advised to report new or worsening vision changes promptly so clinicians can adjust treatment and arrange eye evaluation.
Why is Blenrep monitored so closely for the eyes?
Because eye-related side effects can occur during treatment, patients need scheduled eye checks and instructions on when to seek urgent care if symptoms arise [1].
Has Blenrep been approved and where can I confirm details?
You can confirm approved indications, dosing schedule, and safety warnings in the product’s prescribing information and regulator-issued labeling for your country or region [1].
Sources
[1] https://www.ema.europa.eu/en/medicines/human/EPAR/blenrep